Prima BioMed Becomes Immutep
27 Noviembre 2017 - 6:12PM
We refer to shareholder approval granted at the Company’s Annual
General Meeting held on 17 November 2017 to change the name of the
Company from ‘Prima BioMed Ltd’ to ‘Immutep Limited’.
The Company is pleased to advise that the name
Immutep Limited has been formally adopted after ASIC
registration.
The ASX has been informed and the Company will
trade under the new ticker IMM from 1 December 2017.
The Company will also trade under the NASDAQ ticker
of IMMP.
For further information please
contact:
U.S. Investors:Jay Campbell,
Vice President of Business Development and Investor Relations,
Prima BioMed+1 (917) 860-9404; jay.campbell@primabiomed.com.au
Matthew Beck, The Trout Group LLC+1 (646)
378-2933; mbeck@troutgroup.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immutep Limited (NASDAQ:PBMD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Immutep Limited (NASDAQ): 0 recent articles
Más de Artículos de Noticias